Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9021
Title: | Modulating the PI3K Signalling Pathway in Activated PI3K Delta Syndrome: a Clinical Perspective |
Authors: | Berglund, Lucinda J. |
WSLHD Author: | Berglund, Lucinda J. |
Issue Date: | 2023 |
Citation: | Journal of Clinical Immunology 44(1):34, 2023 |
Abstract: | Activated phosphoinositide-3-kinase (PI3K) delta syndrome (APDS) is an inborn error of immunity characterised by immune dysregulation. Since the discovery of genetic mutations resulting in PI3Kdelta overactivation, treatment of APDS patients has begun to focus on modulation of the PI3K pathway in addition to supportive therapies. The mTOR inhibitor sirolimus has been used effectively for some clinical manifestations of this condition, however the arrival of specific PI3Kdelta inhibitor leniolisib has shown promising early results and may provide a more targeted approach. This review summarizes key aspects of PI3K pathway biology and discusses potential options for nuanced modulation of the PI3K pathway in APDS from a clinical perspective, highlighting differences from PI3K inhibition in haematological malignancies. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/9021 |
DOI: | https://dx.doi.org/10.1007/s10875-023-01626-0 |
Journal: | Journal of Clinical Immunology |
Type: | Journal Article |
Study or Trial: | Review |
Department: | Immunopathology |
Keywords: | Immunologic Deficiency Syndromes Primary Immunodeficiency Diseases Phosphatidylinositol 3-Kinase |
Appears in Collections: | Westmead Hospital 2019 - 2024 |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.